Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01161446 · ClinicalTrials.gov registry record · NA

Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)

A NA study of HIV, sponsored by University of Washington.

Completed
Registry status
NA
Development phase
230
Enrollment target
1
Study location

NCT01161446 is a NA study of HIV that has completed, run by University of Washington. The registered enrollment target is 230 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01161446, a NA study of HIV, has completed, sponsored by University of Washington.

COMPLETED
Registry status
NA
Development phase
230 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether the availability of home self-testing for HIV will increase HIV testing frequency among men who have sex with men without negatively impacting their risk for HIV acquisition.

Conditions Studied

Interventions

  • BEHAVIORAL Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
  • DEVICE Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test

Study Locations (1)

Washington

  • Public Health - Seattle & King County STD Clinic, located at Harborview Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2010-07
Est. Completion 2014-12
Phase NA

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT01161446

The ClinicalTrials.gov registry entry for NCT01161446 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (48% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test is the first listed.

NCT01161446 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT01161446 about?

NCT01161446 is a clinical study titled "Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)". The purpose of this study is to determine whether the availability of home self-testing for HIV will increase HIV testing frequency among men who have sex with men without negatively impacting their risk for HIV acquisition.

What is the current status of trial NCT01161446?

This trial is currently completed. It is a NA study. The enrollment target is 230 participants. The study started on 2010-07. Estimated completion is 2014-12.

What conditions does trial NCT01161446 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT01161446?

The interventions under investigation include: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test (BEHAVIORAL), Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test (DEVICE).

Who is sponsoring clinical trial NCT01161446?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01161446 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.